Related Experiment Video
Updated: Jun 21, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Arsonoliposomes for the potential treatment of medulloblastoma
Marco E Favretto1, Showan Marouf, Panagiotis Ioannou
1Medway School of Pharmacy, University of Kent, Central Avenue, Chatham Maritime, Kent, ME4 4TB, UK.
Purpose:
To investigate the arsonoliposome effect on medulloblastoma cells (VC312Rs) related to uptake, endocytotic mechanism and cell viability.
Methods:
VC312R viability in presence of either arsonoliposomes or stealth liposomes was studied using MTT assay for 1-4 days. Fibroblasts (3T3) were used as control. Apoptosis was studied for 2 h, 5 h and 24 h. Bodipy-labelled arsonoliposome uptake (time- and dose-dependent) was estimated using FACS analysis. The endocytotic mechanism was investigated using inhibitors of clathrin- (chlorpromazine) and caveolae-mediated endocytosis (filipin).
Results:
Arsonoliposomes affected significantly the VC312R viability compared to 3T3 cells and induced apoptosis to VC312Rs after 2 h of incubation. Apoptosis was not observed for 3T3 cells. Liposome uptake versus time showed a bimodal pattern. Clathrin-mediated endocytosis was the main endocytotic mechanism at low lipid concentrations and caveolae at higher ones; thus, dose-dependent uptake did not show a plateau at increased lipid concentrations.
Conclusions:
Arsonoliposomes showed "selective" toxicity towards medulloblastoma cells inducing apoptosis after 2 hs of incubation. Therefore, arsonoliposomes are promising anticancer vehicles for brain tumour treatment.
Insights
Arsonoliposomes demonstrate selective toxicity against medulloblastoma cells, inducing apoptosis rapidly. These liposomes show promise as novel anticancer vehicles for brain tumor treatment.
Area of Science:
- Nanomedicine
- Cancer Biology
- Drug Delivery Systems
Background:
- Medulloblastoma is a common pediatric brain tumor.
- Developing targeted therapies is crucial for improving treatment outcomes.
- Liposomes offer potential as drug delivery vehicles for cancer treatment.
Purpose of the Study:
- To evaluate the efficacy of arsonoliposomes against medulloblastoma cells.
- To investigate the cellular uptake mechanisms and effects on cell viability.
- To determine the potential of arsonoliposomes as anticancer agents.
Main Methods:
- Cell viability was assessed using MTT assays in VC312R medulloblastoma cells and 3T3 fibroblasts.
- Apoptosis induction was studied over time.
- Arsonoliposome uptake and endocytosis pathways (clathrin- and caveolae-mediated) were analyzed using FACS and specific inhibitors.
Main Results:
- Arsonoliposomes significantly reduced medulloblastoma cell viability and induced apoptosis within 2 hours.
- Uptake of arsonoliposomes exhibited a time- and dose-dependent bimodal pattern.
- Clathrin-mediated endocytosis was dominant at lower concentrations, while caveolae-mediated endocytosis prevailed at higher concentrations.
Conclusions:
- Arsonoliposomes exhibit selective toxicity towards medulloblastoma cells.
- The selective toxicity is mediated by apoptosis induction.
- Arsonoliposomes represent a promising therapeutic strategy for brain tumors.
